We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Stability of Fecal Specimens for Bacterial Diagnostics Investigated

By LabMedica International staff writers
Posted on 23 Oct 2014
To test for Clostridium difficile in stool specimens transported from remote geographic locations is a challenge due to long transit times, often at room temperature.

Discrepancies in C. More...
difficile detection rates using nucleic acid amplification tests (NAAT) and antigen, culture and cytopathic effect (CPE) tests have been reported which may be due differences in the load of organisms in the stool, sometimes very low in asymptomatic carriage, and determining the viable count for C. difficile may be needed to differentiate between asymptomatic colonization versus true disease.

Microbiologists at the St. Boniface Research Center (Winnipeg, MB, Canada) assessed the impact of storage at room temperature versus 4 °C for up to 72 hours on the stability of glutamate dehydrogenase antigen, Toxin A and B antigens, toxigenic culture and cytopathic effect testing. Twelve diagnostic stool samples that were tested on the day of collection and shown to be C. difficile toxin positive were used for this study. Sample aliquots of each stool were stored at room temperature and 4 °C and testing was repeated at 24, 48 and 72 hours.

Stools that were positive for the presence of glutamate dehydrogenase (GD) using the C.DIFF QUIK CHEK kit (TECHLAB; Blacksburg, VA, USA) and also positive for the presence of Toxin A/Toxin B when tested by TECHLAB’s TOX A/B QUIK CHEK kit were included in the study. Cytopathic effect (CPE) tests were conducted using Human Foreskin Fibroblast cells (Inter Medico; Markham, ON, Canada). The pellet from the sample used for the CPE test were processed and used to inoculate Clostridium difficile moxalactam norfloxacin (CDMN) agar (Oxoid Company; Nepean, ON, Canada). The glutamate dehyrdogenase antigen and toxigenic stool culture tests were shown to be 100% reproducible at room temperature and 4 °C for up to 72 hours. Toxin A and B antigen deteriorated to 70% by 72 hours at room temperature, but was 90% reproducible if held at 4 °C. The cytopathic effect assay was 90% reproducible by 72 hours at room temperature and 4 °C.

The authors concluded that if stool samples are held at room temperature, the Toxin A/B antigen testing is only stable for 48 hours and by 72 hours is only 70% sensitive. They recommended that for stool samples received from remote geographic locations where transport is at room temperature and may be up to 72 hours, a combination of GD antigen screening combined with NAAT is used to ensure optimal sensitivity. The study was published on June 30, 2014, in the Journal of Medical Microbiology & Diagnosis.

Related Links:

St. Boniface Research Center 
TECHLAB 
Inter Medico



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.